THRV-1268, a novel and potent SGK1 inhibitor, improved adverse cardiac remodeling beyond empagliflozin, an SGLT2 inhibitor, by reducing inflammation and fibrosis mechanisms in heart failure.

29 August 2025 (07:00 - 18:00)

Organised by:

Sign in for access options

Sign in for access options

About the speaker

Doctor Saumya Das

Massachusetts General Hospital - Harvard Medical School, Boston (United States of America)

3 More presentations in this session

Presentation thumbnail

Right vs. left cardiac function and structure: impact of SGLT2i in acute decompensate heart failure with central sleep apnea

Assistant Professor P. Kalaydzhiev (Sofia, BG)

Abstract Slides Video

Presentation thumbnail

Two years follow-up of use of SGLT2 inhibitors in HFrEF patients hospitalized for decompensation

Associate Professor V. Vintila (Bucharest, RO)

Abstract Slides Video

Presentation thumbnail

SGLT2 inhibitors improve cardiovascular clinical outcomes in patients undergoing anthracycline chemotherapy: a systematic review and meta-analysis of 13,333 patients.

Doctor L. Spadafora (Latina, IT)

Abstract Slides Video

Access the full session

Session thumbnail

SGLT2 inhibitors in heart failure: prevention and treatment

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025

You may be interested in

Congress Presentation

Effects of empagliflozin on cardio-renal interaction in heart failure with reduced ejection fraction: results from in-vivo experiments and the CINNAMON-study

Congress Presentation

NAN-CS101: A first-in-human Phase 1 open-label dose-escalation study of AB-1002 gene therapy for the treatment of NYHA class III heart failure

Congress Presentation

Targeting Cysteine 42 in PKGIa limits diastolic dysfunction in HFpEF

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources